The present study suggests that HMGB1 is a prognostic factor and potential biomarker for survival in patients not treated with adjuvant chemotherapy with adenocarcinoma of the ampulla of Vater not treated with adjuvant chemotherapy. The gene discussed is HMGB1; the disease is ampulla of vater adenocarcinoma.